2008
Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma
Arcaini L, Montanari F, Alessandrino EP, Tucci A, Brusamolino E, Gargantini L, Cairoli R, Bernasconi P, Passamonti F, Bonfichi M, Zoli V, Bottelli C, Calatroni S, Troletti D, Merli M, Pascutto C, Majolino I, Rossi G, Morra E, Lazzarino M. Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. Annals Of Oncology 2008, 19: 1331-1335. PMID: 18344536, DOI: 10.1093/annonc/mdn044.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnthracyclinesAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, CD20Antigens, CD34Antineoplastic Combined Chemotherapy ProtocolsBleomycinBone Marrow PurgingCombined Modality TherapyCyclophosphamideCytarabineDisease ProgressionDisease-Free SurvivalDoxorubicinDrug Administration ScheduleEtoposideFemaleFollow-Up StudiesGenes, bcl-2Granulocyte Colony-Stimulating FactorHematopoietic Stem Cell MobilizationHumansImmunologic FactorsImmunosuppressive AgentsKaplan-Meier EstimateLymphoma, FollicularMaleMiddle AgedMultivariate AnalysisPeripheral Blood Stem Cell TransplantationRecurrenceRemission InductionRituximabTime FactorsTransplantation, AutologousTreatment OutcomeVincristineConceptsProgression-free survivalRefractory follicular lymphomaHigh-dose therapyFollicular lymphomaFive-year progression-free survivalPeripheral blood stem cell mobilizationBlood stem cell mobilizationEnd pointHigh-dose AraC.Persistent clinical remissionPrimary end pointSecondary end pointsStem cell harvestStem cell mobilizationBcl-2 rearrangementClinical remissionComplete remissionMolecular remissionPartial responseComplete responseClinical outcomesCell mobilizationMedian numberImmunochemotherapyPatients
2006
Role of the molecular staging and response in the management of follicular lymphoma patients
Arcaini L, Colombo N, Bernasconi P, Calatroni S, Passamonti F, Orlandi E, Bonfichi M, Burcheri S, Della Porta M, Rumi E, Montanari F, Algarotti A, Pascutto C, Lazzarino M. Role of the molecular staging and response in the management of follicular lymphoma patients. Leukemia & Lymphoma 2006, 47: 1018-1022. PMID: 16840191, DOI: 10.1080/10428190500467834.Peer-Reviewed Original ResearchConceptsBcl-2/IgH rearrangementBcl-2 rearrangementBcl-2-negative patientsBcl-2 positive patientsPeripheral bloodMedian EFSMolecular respondersBone marrowNegative patientsPositive patientsClinical featuresBetter EFSIgH rearrangementsMedian event-free survivalBcl-2 negative casesEvent-free survivalFirst-line therapyCohort of patientsFollicular lymphoma patientsBcl-2Onset of diseaseMolecular responseBcl-2-positive casesInitial stagingLymphoma patients
2004
Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies
Alessandrino EP, Bernasconi P, Colombo AA, Caldera D, Malcovati L, Troletti D, Vanelli L, Varettoni M, Montanari F, Lazzarino M. Reduced-intensity conditioning regimen with thiotepa and fludarabine followed by allogeneic blood stem cell transplantation in haematological malignancies. Bone Marrow Transplantation 2004, 34: 1039-1045. PMID: 15516936, DOI: 10.1038/sj.bmt.1704717.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntineoplastic Combined Chemotherapy ProtocolsBlood TransfusionFemaleGraft SurvivalHematologic NeoplasmsHumansMaleMiddle AgedPeripheral Blood Stem Cell TransplantationRecurrenceRemission InductionSurvival AnalysisThiotepaTransplantation ChimeraTransplantation ConditioningTransplantation, HomologousVidarabineConceptsAllogeneic blood stem cell transplantationPeripheral stem cell transplantBlood stem cell transplantationReduced-intensity conditioning regimenStandard myeloablative regimenTransplant-related mortalityPoor performance statusStem cell transplantStem cell transplantationOverall survival probabilityMyeloablative regimenNonrelapse causesComplete remissionConditioning regimenMild nauseaPreparative regimenAdverse eventsPerformance statusMedian ageRBC transfusionCell transplantCell transplantationHaematological malignanciesSerum amylasePatients